Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prediction of Potential Drug Interaction With CYP2C9 Substrate by Using Phenytoin Metabolic Ratio as a Marker of Its Activity in-Vivo.

NCT00226538 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT00226538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00226538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prediction of Potential Drug Interaction With CYP2C9 Substrate by Using Phenytoin Metabolic Ratio as a Marker of Its Activity in-Vivo.
Lead sponsor
Hadassah Medical Organization
Phase
Not applicable
Overall status
Completed
Start date
August 31, 1999
Completion date
Not reported
Enrollment
16
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers